Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 818 results for "Treatment For Multiple Sclerosis"

New Treatment for Multiple Sclerosis Being Investigated by Researchers
Med India

Baylor Research Institute Immunology Researchers Obtaining Pro...

Thanks to new insights related to dendritic cell vaccines, researchers are investigating a potential vaccine for MS treatment and prevention at the Baylor Institute for Immunology Research (BIIR), a division of Baylor Research Institute. If future ... Infrosoft, 4 hours ago

32 images for Treatment For Multiple Sclerosis

MedIndia, 3 weeks ago
Medical Xpress, 1 month ago
Lancaster & Morecambe Citizen, 1 month ago
The Guardian Express, 1 month ago
International Journal of Dermatology, 1 week ago
I Stock Analyst, 2 weeks ago
Bioresearch Online, 1 month ago
HamptonRoads.com, 1 month ago
YNN Rochester, 1 month ago
Sunshine Coast Daily, 4 weeks ago

Drug Candidate for Multiple Sclerosis Shows New Promise

The Scripps Research Institute have discovered and synthesized a new drug candidate for relapsing multiple sclerosis. According to the results from a six-month Phase 2 study of 258 multiple sclerosis patients, the drug candidate RPC1063 reduced ...
 MedIndia1 day ago Multiple Sclerosis Drug in Trials Reduces Relapse  EMax Health1 day ago Another new drug shows promise against multiple sclerosis  Consumer Affairs1 day ago Multiple Sclerosis new drug candidate has promise  Examiner.com2 days ago
[x]  

Biogen Idec Announces Strides In Clinical Studies For MS Treatments

By Lori Clapper Biogen Idec announced clinical study results for three of its Multiple Sclerosis (MS) treatments at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European ...
 Bioresearch Online5 days ago Genzyme announces positive results from multiple sclerosis extension study  Individual.com5 days ago Plegridy (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients  European Pharmaceutical Review4 days ago Teva and Active Biotech announce encouraging data from multiple sclerosis study  Individual.com6 days ago

Acorda Therapeutics and HealthCore to Present Ampyra Data at Americas Committee for Treatment and Research in Multiple Sclerosis/European Committee for Treatment and Research in Multiple Sclerosis Meeting

Acorda Therapeutics and HealthCore will present results from a retrospective claims database study assessing use of Ampyra (dalfampridine) Extended Release Tablets, 10 mg, at the 2014 Joint Americas Committee for Treatment and Research in Multiple ...
 Individual.com1 week ago

Antisense receives patent for treatment of multiple sclerosis from EPO

(MarketLine via COMTEX News Network) -- Antisense Therapeutics Limited has received a patent entitled, methods for treating multiple sclerosis using antisense oligonucleotides, from the European Patent Office, or EPO, which extends coverage of the ...
 PredictWallStreet1 day ago

Update on multiple sclerosis treatments

Review article: Current opinion | Published 23 September 2014 , doi: 10.4414/smw.2014.14012 Cite this as: Swiss Med Wkly. 2014;144:w14012 Claire Bridel a , Patrice H. Lalive a,b a Department of Clinical Neurosciences, Division of ...
 Swiss Medical Weekly8 hours ago Peglylated Interferon Maintains Benefits Through 2 Years in Treatment of Multiple Sclerosis: Presented at ECTRIMS  FirstWord Pharma1 week ago L-Carnitine Not Effective in Treatment of Fatigue in Multiple Sclerosis: Presented at ECTRIMS  FirstWord Pharma1 week ago

EU regulator warns on possible MS drugs side effects

FRANKFURT (Reuters) - Europe's drug safety regulator said multiple sclerosis treatments known as interferon beta need stronger label warnings because some patients treated with the drugs have suffered side effects affecting the kidney and other organs.
 Reuters1 month ago

MS Spasticity Responds to Marijuana Extract

BOSTON — A new study finds measurable benefit on lower-limb spasticity in patients with progressive multiple sclerosis (MS) with a tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray ( Sativex , GW Pharmaceuticals). "Our findings ...
 General Medicine eJournal11 hours ago Beat Spasticity in Multiple Sclerosis with Marijuana  EMax Health3 days ago Sativex Helps MS Spasticity in Objective Tests  MedPage Today6 days ago Kessler pilot study demonstrates benefits of wellness program for people with MS  EurekAlert!1 day ago

Invitation - Quebec Summit on Multiple Sclerosis - Discover the latest Quebec research projects on multiple sclerosis!

MS Deepelling at the Summit - Watch our participants swoop down a seven-storey building! MONTREAL, Sept. 23, 2014 /CNW Telbec/ - Research on multiple sclerosis is progressing in leaps and bounds, and Quebec is undeniably contributing to advances ...
 Canada NewsWire14 hours ago

Iranian scientists discover direct relation of MS, diet

Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system and renders the brain ineffective in sending messages to the rest of the body. Though we know relatively little about multiple sclerosis. Recently, it has been ...
 Mehr News2 days ago Robotics competitions  Iran Daily23 hours ago Kashan University synthesizes controlled nanostructures  Iran Daily23 hours ago Iranians discover direct MS-diet link  Iran Daily23 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less